AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00820222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
Study NCT00820222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
Study NCT00820222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: oral medication; daily dose taken once a day
Study NCT02255500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL Infiltration
Description: A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
Study NCT02994732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BVD-523
Description: \[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
Study NCT02684643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced individualised therapy
Description: additional dialysis dosage, modification of medication and prescribed dietary plan
Study NCT00820222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
Study NCT00733096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Two transforaminal epidural steroid injections with 60 mg, two weeks apart
Study NCT02854254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripherally inserted central catheter
Description: peripherally inserted central catheter
Study NCT02854254 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: peripherally venous access
Description: standard over-the-needle intravenous catheter
Study NCT02434965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPDSC
Description: Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
Study NCT02434965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cord blood
Description: Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
Study NCT06005519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: low AGE diet education
Description: Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.
Study NCT03104257 — intervention group
Intervention type: DRUG
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Study NCT00787501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Description: SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
Study NCT00787501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
Study NCT01943240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels
Study NCT01943240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels
Study NCT01943240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 cc of 0.375% ropivacaine pectoral nerve block
Study NCT03589755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation
Description: The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
Study NCT00705887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Enhancement Intervention
Description: The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
Study NCT00569868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000.
Study NCT02684643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-enhanced individualised therapy
Description: modified medication, prescribed dietary plan and regular three times/week dialysis dosage
Study NCT00733096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Two transforaminal epidural saline injections, two weeks apart
Study NCT00440830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: nicotine patch (0,5,10 or 15mg/day) applied to smokers
Study NCT00440830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
Study NCT00440830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo patch applied to smokers
Study NCT00440830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo patch applied to nonsmokers
Study NCT01300260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously
Study NCT01300260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously
Study NCT01300260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Administered intravenously
Study NCT01300260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Administered intravenously
Study NCT02684643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular intervention
Description: Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
Study NCT01300260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Administered intravenously
Study NCT01789606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Description: Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Study NCT02667470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Oral
Study NCT03903939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: continuously infusion for 72 hours 1 ng/kg/min
Study NCT03903939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: continuously infusion for 72 hours equal volume to Iloprost
Study NCT03180307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: 0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
Study NCT03180307 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: OTL38
Description: 0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
Study NCT03180307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared camera imaging system
Description: Infrared imaging used to excite OTL38 for fluorescence
Study NCT03180307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
Study NCT03180307 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: laparotomy
Description: primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
Study NCT01909765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal slit
Description: Skin and mucosa incision made together
Study NCT01909765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double incision
Description: Skin and mucosa incision made separately
Study NCT04585607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A medium cut-off dialyzer (Theranova) will be used for HDx.
Description: A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.~HD with MCO dialyzer (Theranova 400®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)
Study NCT04585607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A synthetic high-flux dialyzer (Polyflux)
Description: A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.
Study NCT03401060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
Study NCT03401060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
Study NCT01354366 — intervention group
Intervention type: OTHER
Intervention: Infant formula
Study NCT03507075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency management: Contingent incentives
Description: Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
Study NCT03507075 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Contingency management: Noncontingent incentives
Description: Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
Study NCT03902119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INYBI tool
Description: Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
Study NCT03902119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual suboccipital inhibition
Description: Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
Study NCT01590654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Study NCT01590654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Study NCT01214707 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: Exercise during EMU stay
Study NCT01441674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy
Description: There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
Study NCT00628680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAT-023 solution (Zuragen)
Description: Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
Study NCT04178746 — intervention group
Intervention type: DEVICE
Intervention: Artemis Neuro Evacuation Device
Description: The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope.
Study NCT00138944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: od
Study NCT00138944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: 50mg od
Study NCT00930150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training
Description: Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
Study NCT00930150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer control
Description: Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
Study NCT00930150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging groups
Description: Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
Study NCT00930150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and wellness groups
Description: Weekly group meetings that teach participants health and wellness skills
Study NCT03732885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: densah burs osseo densification drills
Description: maxillary sinus floor elevation during implant placement using Densah burs
Study NCT03732885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summer's Osteotomes
Description: maxillary sinus floor elevation during implant placement using Summer's Osteotomes
Study NCT04009421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary artery plaque assessment by CT coronary angiography QAngio CT RE
Description: Assessment of segmental plaque volume and composition
Study NCT03805932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox-tdfk
Description: Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
Study NCT00628680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
Study NCT05138731 — intervention group
Intervention type: OTHER
Intervention: treatments according guidelines
Description: different group intervened with different treatment following guidelines/consensuses accordingly
Study NCT03805932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
Study NCT03805932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ruxience
Description: Ruxience will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)
Study NCT03805932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 12 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Administer 0.5-2 hours before rituximab/Ruxience. If participant has previous reaction to rituximab/Ruxience, give 12mg. If participants tolerate rituximab/Ruxience without problems, may hold at discretion of provider. Pre-medications are given prior to rituximab/Ruxience on day 1.
Study NCT03805932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
Study NCT03805932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25-50 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Pre-medications are given prior to rituximab/Ruxience on day 1. May be given prior to moxetumomab pasudotox-tdfk at discretion of principal investigator.
Study NCT03805932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
Study NCT02951429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
Study NCT02951429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
Study NCT02951429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with sildenafil.
Study NCT02951429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil will be given as 20 mg, TID.
Study NCT02798471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: 15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
Study NCT02798471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
Study NCT03221361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermoplastic complete denture
Description: a device used ti substitute teeth for edentlous patient made of thermoplastic resin
Study NCT03221361 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional acrylic resin complete denture
Description: A device used to substitute the teeth for edentlous patient made of acrylic resin